Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase II drugs for Kaposi Sarcoma have an 8% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bifikafusp alfa + onfekafusp alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bifikafusp alfa + onfekafusp alfa overview
Daromun (L19-IL2 + L19-TNF) is under development for the treatment of metastatic melanoma, non-melanomatous skin cancer including basal cell carcinoma (basal cell epithelioma), squamous cell carcinoma, stage III and IV unresectable melanoma patients, cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma, keratoacanthoma, tumoral cutaneous T-cell lymphoma, Kaposi’s sarcoma or Adnexal tumors of the Skin and other types of skin cancer. The drug candidate is administered intratumorally and intralesional. L19-IL2 and L19-TNF are recombinant fusion proteins, composed of the single-chain monoclonal antibody fragment (L19). L19-IL2 is composed of human recombinant interleukin-2 (IL-2). L19-TNF is composed of human recombinant tumor necrosis factor-alpha. The drug candidate acts by targeting fibronectin and interleukin 2 receptor subunit alpha (IL2RA).
Philogen overview
Philogen is a biotechnology company that develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company’s product portfolio include Dodekin, Dekavil, NidlegyTM, Fibromun, Darleukin, and ABBV-022. The company provides dekavil and tetravil and others targeted at the treatment of severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. It offers DNA-encoded chemical libraries, antibody drug conjugates, immunocytokines, and antibody libraries, discovery of vascular targets, vascular targeting and easy iodine technology. The company is also advancing clinical development programs for the treatment of cancer and of chronic diseases. Philogen is headquartered in Siena, Italy.
For a complete picture of Bifikafusp alfa + onfekafusp alfa’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
